Dr Abughanimeh on the Evolution of Targeted Therapy in EGFR+ NSCLCByOmar Abughanimeh, MDOctober 16th 2023Omar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.